Evidence map›Paper›PMID 18991785›Full record

ReviewRecent patents on anti-cancer drug discovery2008

Update on aurora kinase inhibitors in gynecologic malignancies.

Xia Tao, Hye S Chon, Siqing Fu, John J Kavanagh, Wei Hu

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Recent patents on anti-cancer drug discovery, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Frontiers in oncology · 2020
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Xia TaoDepartment of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Hye S Chon
Siqing Fu
John J Kavanagh
Wei Hu
The University of Texas MD Anderson Cancer Center · USAdvanced Cancer Therapeutics · USBaylor College of Medicine · US

Funding

SPORE in LymphomaP50CA130805 · NCI · UNIVERSITY OF ROCHESTER · PI BERNSTEIN, STEVEN H · 2008 to 2012
$11.7M
NCI NIH HHS P50 CA130805
6 · The paper itself

Abstract

Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis and play a role in tumorigenesis and tumor progression in humans. Aurora kinase A and Aurora kinase B are overexpressed in some gynecologic cancers, and their overexpression is associated with poor prognosis. Thus, targeting of Aurora kinases has become an attractive strategy for pharmaceutical companies, who have developed more than 30 Aurora kinase inhibitors for treatment of cancers. Some of these inhibitors have been shown to be effective in targeted therapies for human cancer, and others are currently being investigated. In this review, we summarize the most recent advances in preclinical studies and clinical trials of patented Aurora kinase inhibitors for gynecologic tumors.

Indexed as

AnimalsAntineoplastic AgentsAurora Kinase AAurora Kinase BAurora KinasesClinical Trials as TopicDrug Delivery SystemsDrug Evaluation, PreclinicalEnzyme InhibitorsFemaleGene Expression Regulation, NeoplasticGenital Neoplasms, FemaleHumansPatents as TopicProtein Serine-Threonine KinasesAntineoplastic AgentsAURKA protein, humanAURKB protein, humanAurora Kinase AAurora Kinase BAurora KinasesEnzyme InhibitorsProtein Serine-Threonine Kinases

Identifiers

PMID18991785
PMCPMC3039426
OpenAlexW2048257547

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.